Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.71 |
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603687 | 1.00 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL8279093 | 1.00 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL14618135 | 0.89 | SLC7A5 (0.59) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL17913929 | 0.86 | SLC7A5 (0.59) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL28297995 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL28270669 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL6374042 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL18309081 | 0.84 | SLC7A5 (0.67) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| Tyrosine SCHEMBL5222909 | 0.84 | SLC7A5 (0.92) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL358908 | 0.83 | SLC7A5 (0.71) | SLC7A5ESR1ESR2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4137496-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-30 | — | — | US | disclosed |
| WO-2018080789-A1 | LUBRICATING OIL COMPOSITIONS COMPRISING A BIODIESEL FUEL AND A MANNICH CONDENSATION PRODUCT | CHEVRON ORONITE TECHNOLOGY B.V. (NL) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017208031-A1 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | SMALL PHARMA LTD (GB) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017167929-A1 | AMPHIPHILIC MONOMERS BASED NANOVECTORS AND THEIR USE FOR SIRNA DELIVERY | UNIVERSITE DE STRASBOURG (FR) | 2017-10-05 | — | — | WO | disclosed |
| US-20100160210-A1 | GUANIDINIUM DELIVERY CARRIERS | NITTO DENKO CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1623977-B1 | INTERMEDIATE COMPOUND WHICH IS USED FOR THE PREPARATION OF PIOGLITAZONE | MEDICHEM SA (ES) | 2007-11-07 | — | — | EP | disclosed |
| US-7214321-B2 | Adsorption method and ligands | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-08 | — | — | US | disclosed |
| US-7214321-B2 | Adsorption method and ligands | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-08 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| WO-2007001926-A2 | LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160210-A1 | GUANIDINIUM DELIVERY CARRIERS | SLC2A9, SLC29A2, SLC2A4 | SLC7A5 68/4885ESR1 2201/4885ESR2 1429/4885 |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | SLC7A5 1399/4885ESR1 2065/4885ESR2 1956/4885 |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | SLC7A5 1953/4885ESR1 2704/4885ESR2 531/4885 |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR1D | SLC7A5 435/4885ESR1 1428/4885ESR2 424/4885 |
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | TTPA, SREBF1, SREBF2 | SLC7A5 2054/4885ESR1 603/4885ESR2 452/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | SLC7A5 1522/4885ESR1 623/4885ESR2 840/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | SLC7A5 1362/4885ESR1 1522/4885ESR2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.